Study #2018-0935
An Open Label, Phase II Investigator Initiated Study Of Venetoclax And Acalabrutinib In Previously Treated Relapsed/Refractory Patients With Mantle Cell Lymphoma (MCL)
MD Anderson Study Status
Not Accepting
Treatment Agent
Acalabrutinib, Venetoclax
Description
This phase II trial studies how well venetoclax and acalabrutinib work in treating patients with mantle cell lymphoma that did not respond to previous treatment or has come back. Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to stay alive. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and acalabrutinib together may kill more cancer cells in patients with mantle cell lymphoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, CD5 Positive, FCER2 Negative, Pleomorphic Variant Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, t(11, 14)(q13, q32)
Study phase:
Phase II
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.